

# Karyopharm to Participate at Upcoming Investor Conferences

NEWTON, Mass., May 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in May:

## **H.C. Wainwright 4th Annual BioConnect Investor Conference**

Format: Fireside chat

Date: Tuesday, May 19, 2026

Time: 9:00 a.m. ET

## **RBC 2026 Global Healthcare Conference**

Format: Fireside chat

Date: Tuesday, May 19, 2026

Time: 3:35 p.m. ET

A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company's website, <http://investors.karyopharm.com/events-presentations>, and will be available for replay following the event.

## **About Karyopharm Therapeutics**

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO<sup>®</sup> (selinexor), is approved in the U.S. and marketed by the Company in two oncology indications. It has also received regulatory approvals in various indications in more than 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO<sup>®</sup>) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, and myelofibrosis. For more information about our people, science and pipeline, please visit [www.karyopharm.com](http://www.karyopharm.com), and follow us on [LinkedIn](#) and on X at [@Karyopharm](#).

XPOVIO<sup>®</sup> and NEXPOVIO<sup>®</sup> are registered trademarks of Karyopharm Therapeutics Inc.

SOURCE Karyopharm Therapeutics Inc.

For further information: CONTACTS: Investors: Brendan Strong, Senior Vice President, Investor Relations, 617.762.2661, [brendan.strong@karyopharm.com](mailto:brendan.strong@karyopharm.com); Media: Mary Ann Ondish, Head of Corporate Communications, 914.552.4625, [Maryann.ondish@karyopharm.com](mailto:Maryann.ondish@karyopharm.com)

---

<https://investors.karyopharm.com/2026-05-12-Karyopharm-to-Participate-at-Upcoming-Investor-Conferences>